1. Generics Bulletin
  2. >>Business
  3. >>Deals

Olon Expands With GTP Acquisition

Italian Ingredients Producer Snaps Up French Biotech CDMO

 
• By Dave Wallace

Italy’s Olon Group has acquired French biotech contract development and manufacturing organization GTP Bioways, in a move that Olon says will allow it to “expand and diversify its technological offerings.”

Paolo Tubertini
Olon CEO Paolo Tubertini • Source: Olon

Italian active pharmaceutical ingredients specialist Olon Group has struck a deal to acquire French biotech contract development and manufacturing organization GTP Bioways, in a move that Olon says will allow it to “expand and diversify its technological offerings.”

GTP Bioways specializes in R&D Services, process development and production of monoclonal antibodies, enzymes, proteins, nanodrugs, antibody-drug conjugates and fill-finish....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Polpharma Biologics And Fresenius Kabi Team Up On Entyvio Biosimilar

 
• By Urtė Fultinavičiūtė

Fresenius Kabi has picked up commercialization rights to Polpharma Biologics’ vedolizumab biosimilars in almost all markets. Still, the originator Takeda stands solid with no competition expected until at least 2032.

Celltrion And Arrotex Tie Up For A Pair Of First PBS-Listed Australian Biosimilars

 
• By Dean Rudge

Arrotex has entered into a strategic partnership with Celltrion Healthcare Australia to launch two first-to-market biosimilar medicines in Australia. These biosimilars, which treat chronic inflammatory conditions, are now listed on the PBS and available through pharmacies.

BC Partners Bids For Biogaran Buyout – But Will It Face French Pushback?

 
• By Dave Wallace

Private equity firm BC Partners has revealed that it is in exclusive negotiations to acquire Servier’s French generics and biosimilars business Biogaran. But with France’s government having expressed opposition to the sale, could there be strings attached?

Sandoz Strikes $300m Deal With Just-Evotec For French Biosimilars Site

 
• By Dave Wallace

Sandoz has made yet another major move to further bolster its booming biosimilars business, striking a $300m deal to acquire outright a French development and manufacturing facility from existing biosimilars partner Just-Evotec Biologics.

More from Business

Dr Reddy’s On Semaglutide Prospects, Capacity And There’s An IP Hearing To Watch

 
• By Anju Ghangurde

Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.

Teva: Not All Our Biosimilars Need To Be Superstars

 
• By Dean Rudge

With eight biosimilars launching by 2027, Teva sees its biosimilars business not as a one-hit bet, but a portfolio approach. The company spoke about its plans, alongside tariffs and other topics, during its second-quarter earnings call.

BC Partners Bids For Biogaran Buyout – But Will It Face French Pushback?

 
• By Dave Wallace

Private equity firm BC Partners has revealed that it is in exclusive negotiations to acquire Servier’s French generics and biosimilars business Biogaran. But with France’s government having expressed opposition to the sale, could there be strings attached?